Trial · NCT03487549
Results by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 57
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Cohort 1 | 4 | Participants | ||
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) | VP-102 - Cohort 2 | 18 | Participants | ||
| Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Cohort 1 | Baseline | 2.19 | Standard Deviation 1.569 | Number of warts |
| Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84) | Cohort 1 | End of Treatment Visit | -0.95 | Standard Deviation 1.658 | Number of warts |
| Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84). | Cohort 1 | -31.19 | Standard Deviation 42.776 | Percent change | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at any Visit? | 5 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 14 | 0 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 28 | 2 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 42 | 5 | Participants | |
| Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | Cohort 1 | Complete Clearance Reported at Day 84 (EOS) | 4 | Participants | |
| Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84) | VP-102 - Cohort 2 | -0.85 | Standard Deviation 1.064 | change in wart count | |
| Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84) | VP-102 - Cohort 2 | -53.79 | Standard Deviation 55.241 | percentage of change in wart count | |
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | VP-102 - Cohort 2 | Complete Clearance Reported at Day 21 (Treatment Visit 2) | 5 | Participants | |
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | VP-102 - Cohort 2 | Complete Clearance Reported at Day 42 (Treatment Visit 3) | 7 | Participants | |
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | VP-102 - Cohort 2 | Complete Clearance Reported at Day 63 (Treatment Visit 4) | 12 | Participants | |
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | VP-102 - Cohort 2 | Complete Clearance Reported at Day 84 (EOT) | 18 | Participants | |
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | VP-102 - Cohort 2 | Complete Clearance Reported at Day 105 | 16 | Participants | |
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | VP-102 - Cohort 2 | Complete Clearance Reported at Day 126 | 13 | Participants | |
| Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study | VP-102 - Cohort 2 | Complete Clearance Reported at Day 147 | 13 | Participants | |
| Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study. | Cohort 1 | Treatment Visit 2 Day 14 | -0.79 | Standard Deviation 3.637 | Percent change in number of warts |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03487549/results